Clinical Trial Update: Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II safety study of IPI-504 (retaspimycin hydrochloride), an HSP90 inhibitor, in relapsed/refractory stage IIIb or stage IV non-small cell lung cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED